title: Conditioned contribution of peripheral cocaine actions to cocaine reward and cocaine-seeking.
abstract: Cocaine has actions in the peripheral nervous system that reliably precede--and thus predict--its soon-to-follow central rewarding effects. In cocaine-experienced animals, the peripheral cocaine signal is relayed to the central nervous system, triggering excitatory input to the ventral tegmental origin of the mesocorticolimbic dopamine system, the system that mediates the rewarding effects of the drug. We used cocaine methiodide, a cocaine analog that does not cross the blood-brain barrier, to isolate the peripheral actions of cocaine and determine their central and behavioral effects in animals first trained to lever-press for cocaine hydrochloride (the centrally acting and abused form of the drug). We first confirmed with fast-scan cyclic voltammetry that cocaine methiodide causes rapid dopamine release from dopamine terminals in cocaine hydrochloride-trained rats. We then compared the ability of cocaine hydrochloride and cocaine methiodide to establish conditioned place preferences in rats with self-administration experience. While cocaine hydrochloride established stronger place preferences, cocaine methiodide was also effective and its effectiveness increased (incubated) over weeks of cocaine abstinence. Cocaine self-administration was extinguished when cocaine methiodide or saline was substituted for cocaine hydrochloride in the intravenous self-administration paradigm, but cocaine hydrochloride and cocaine methiodide each reinstated non-rewarded lever-pressing after extinction. Rats extinguished by cocaine methiodide substitution showed weaker cocaine-induced reinstatement than rats extinguished by saline substitution. These findings suggest that the conditioned peripheral effects of cocaine can contribute significantly to cocaine-induced (but not stress-induced) cocaine craving, and also suggest the cocaine cue as an important target for cue-exposure therapies for cocaine addiction.
authors.affiliation: Behavioral Neuroscience Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224, USA.
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Zhi-Bing
authors.initials: ZB
authors.lastname: You
authors.forename: Erik B
authors.initials: EB
authors.lastname: Oleson
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Cheer
authors.forename: Stephanie
authors.initials: S
authors.lastname: Myal
authors.forename: Roy A
authors.initials: RA
authors.lastname: Wise
mesh_terms: D000818:Animals; D003042:Cocaine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects*; D003213:Conditioning, Psychological / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism; D058999:Drug-Seeking Behavior / Q000187:drug effects*; D005108:Extinction, Psychological / Q000187:drug effects; D008297:Male; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D012201:Reward; D012646:Self Administration
chemical_list: C076070:cocaine methiodide; D003042:Cocaine; D004298:Dopamine
references.citation: Psychopharmacology (Berl). 1989;97(1):59-64
references.pmid: 2496428
references.citation: Eur J Neurosci. 2001 Feb;13(4):819-28
references.pmid: 11207817
references.citation: Arch Gen Psychiatry. 1986 Feb;43(2):107-13
references.pmid: 3947206
references.citation: Psychopharmacology (Berl). 1995 Jun;119(3):334-41
references.pmid: 7675970
references.citation: Addiction. 2002 Feb;97(2):155-67
references.pmid: 11860387
references.citation: Nat Rev Neurosci. 2011 Jun 02;12(8):479-84
references.pmid: 21633381
references.citation: Psychopharmacology (Berl). 1981;75(2):134-43
references.pmid: 6798603
references.citation: J Neurosci. 2009 Jan 28;29(4):1087-92
references.pmid: 19176817
references.citation: Psychopharmacology (Berl). 1980;71(1):83-9
references.pmid: 6779329
references.citation: Pharmacol Biochem Behav. 1977 Jun;6(6):615-20
references.pmid: 122445
references.citation: J Neurosci. 2000 Feb 15;20(4):1635-42
references.pmid: 10662853
references.citation: J Pharmacol Exp Ther. 2009 Oct;331(1):204-11
references.pmid: 19602552
references.citation: Science. 2012 Apr 13;336(6078):241-5
references.pmid: 22499948
references.citation: Neuron. 2005 May 19;46(4):661-9
references.pmid: 15944133
references.citation: J Neurosci. 2007 Sep 26;27(39):10546-55
references.pmid: 17898226
references.citation: Behav Brain Res. 1997 Aug;87(1):111-3
references.pmid: 9331479
references.citation: Can J Psychol. 1977 Dec;31(4):195-203
references.pmid: 608135
references.citation: Psychopharmacology (Berl). 2011 Oct;217(3):387-96
references.pmid: 21494787
references.citation: Psychopharmacology (Berl). 1997 Aug;132(3):289-95
references.pmid: 9292629
references.citation: Br J Addict. 1986 Oct;81(5):655-60
references.pmid: 3466632
references.citation: Addict Behav. 1990;15(4):395-9
references.pmid: 2248112
references.citation: Synapse. 1999 Mar 15;31(4):241-9
references.pmid: 10051104
references.citation: Neurosci Lett. 2011 Oct 17;504(1):13-7
references.pmid: 21888949
references.citation: Nature. 2001 Jul 12;412(6843):141-2
references.pmid: 11449260
references.citation: Biol Psychiatry. 2002 Nov 15;52(10):976-86
references.pmid: 12437938
references.citation: Biol Psychiatry. 2011 Sep 15;70(6):593-8
references.pmid: 21571256
references.citation: J Subst Abuse Treat. 1986;3(1):33-40
references.pmid: 2874232
references.citation: Neurosci Biobehav Rev. 2010 Nov;35(2):285-302
references.pmid: 20109490
references.citation: PLoS One. 2008 Aug 06;3(8):e2846
references.pmid: 18682722
references.citation: Psychol Bull. 1964 May;61:341-61
references.pmid: 14146339
references.citation: J Neurochem. 1988 Oct;51(4):1314-6
references.pmid: 3418351